Transamerica Financial Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.14M | Buy |
8,498
+1,485
| +21% | +$319K | 0.18% | 130 |
|
|
2026
Q1 | $1.53M | Sell |
7,013
-558
| -7% | -$124K | 0.13% | 154 |
|
|
2025
Q4 | $1.73M | Buy |
7,571
+782
| +12% | +$178K | 0.14% | 144 |
|
|
2025
Q3 | $1.57M | Buy |
6,789
+2,055
| +43% | +$418K | 0.13% | 125 |
|
|
2025
Q2 | $879K | Buy |
4,734
+12
| +0.3% | +$2.23K | 0.08% | 169 |
|
|
2025
Q1 | $990K | Sell |
4,722
-885
| -16% | -$172K | 0.1% | 156 |
|
|
2024
Q4 | $997K | Buy |
5,607
+610
| +12% | +$112K | 0.1% | 148 |
|
|
2024
Q3 | $987K | Sell |
4,997
-2,232
| -31% | -$417K | 0.1% | 156 |
|
|
2024
Q2 | $1.24M | Hold |
7,229
| – | – | 0.13% | 116 |
|
|
2024
Q1 | $1.32M | Sell |
7,229
-4,026
| -36% | -$694K | 0.13% | 126 |
|
|
2023
Q4 | $1.75M | Sell |
11,255
-983
| -8% | -$143K | 0.24% | 69 |
|
|
2023
Q3 | $1.82M | Sell |
12,238
-1,079
| -8% | -$158K | 0.25% | 67 |
|
|
2023
Q2 | $1.79M | Buy |
13,317
+1,079
| +9% | +$158K | 0.23% | 72 |
|
|
2023
Q1 | $1.95M | Sell |
12,238
-782
| -6% | -$120K | 0.26% | 65 |
|
|
2022
Q4 | $2.1M | Sell |
13,020
-1,570
| -11% | -$241K | 0.3% | 59 |
|
|
2022
Q3 | $1.96M | Buy |
14,590
+1,629
| +13% | +$234K | 0.29% | 61 |
|
|
2022
Q2 | $1.99M | Buy |
+12,961
| New | +$1.98M | 0.28% | 56 |
|
|
2021
Q3 | – | Sell |
-3
| Closed | -$1K | – | 117 |
|
|
2021
Q2 | $1K | Sell |
3
-12
| -80% | -$1.35K | 0.02% | 78 |
|
|
2021
Q1 | $2K | Hold |
15
| – | – | 0.05% | 62 |
|
|
2020
Q4 | $2K | Buy |
15
+8
| +114% | +$769 | 0.04% | 63 |
|
|
2020
Q3 | $1K | Sell |
7
-15,826
| -100% | -$1.49M | 0.02% | 134 |
|
|
2020
Q2 | $1.55M | Buy |
+15,833
| New | +$1.39M | 0.34% | 56 |
|
|
2019
Q3 | – | Sell |
-2,548
| Closed | -$186K | – | 97 |
|
|
2019
Q2 | $186K | Buy |
+2,548
| New | +$200K | 0.04% | 171 |
|
|
2019
Q1 | – | Sell |
-2,653
| Closed | -$245K | – | 100 |
|
|
2018
Q4 | $245K | Sell |
2,653
-133
| -5% | -$11.7K | 0.06% | 146 |
|
|
2018
Q3 | $264K | Buy |
2,786
+355
| +15% | +$33.7K | 0.06% | 164 |
|
|
2018
Q2 | $226K | Sell |
2,431
-3,618
| -60% | -$353K | 0.05% | 179 |
|
|
2018
Q1 | $573K | Buy |
+6,049
| New | +$664K | 0.08% | 166 |
|
|
2017
Q1 | – | Sell |
-55
| Closed | -$4K | – | 393 |
|
|
2016
Q4 | $4K | Buy |
+55
| New | +$3.36K | ﹤0.01% | 261 |
|
|
2016
Q2 | – | Sell |
-854
| Closed | -$49K | – | 391 |
|
|
2016
Q1 | $49K | Sell |
854
-5,579
| -87% | -$311K | ﹤0.01% | 371 |
|
|
2015
Q4 | $382K | Hold |
6,433
| – | – | 0.03% | 263 |
|
|
2015
Q3 | $350K | Sell |
6,433
-228
| -3% | -$14.8K | 0.03% | 247 |
|
|
2015
Q2 | $448K | Buy |
6,661
+5,360
| +412% | +$350K | 0.03% | 235 |
|
|
2015
Q1 | $77K | Sell |
1,301
-101
| -7% | -$6.1K | 0.01% | 390 |
|
|
2014
Q4 | $92K | Buy |
1,402
+4
| +0.3% | +$252 | 0.01% | 324 |
|
|
2014
Q3 | $81K | Buy |
1,398
+182
| +15% | +$10.1K | 0.01% | 311 |
|
|
2014
Q2 | $69K | Sell |
1,216
-9,444
| -89% | -$495K | 0.01% | 347 |
|
|
2014
Q1 | $548K | Buy |
10,660
+10,227
| +2,362% | +$517K | 0.05% | 144 |
|
|
2013
Q4 | $23K | Hold |
433
| – | – | ﹤0.01% | 399 |
|
|
2013
Q3 | $20K | Hold |
433
| – | – | ﹤0.01% | 385 |
|
|
2013
Q2 | $18K | Buy |
+433
| New | +$18.9K | ﹤0.01% | 367 |
|
Other funds holding ABBV
Transamerica Financial Advisors's ABBV Position: Q2 2026 in Review
Transamerica Financial Advisors increased its AbbVie (ABBV) stake by 21% in Q2 2026, buying an estimated $319K and bringing the position to 8,498 shares worth $2.14M. The position accounts for 0.18% of the portfolio, ranked #130.
Transamerica Financial Advisors first reported a position in ABBV in Q2 2013 and has held it in 40 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Transamerica Financial Advisors held 8,498 shares of AbbVie worth $2.14M as of Q2 2026.
- Transamerica Financial Advisors bought 1,485 AbbVie shares in Q2 2026, an estimated $319K.
- AbbVie made up 0.18% of Transamerica Financial Advisors's portfolio in Q2 2026, its #130 holding.
- Transamerica Financial Advisors first reported a position in AbbVie in Q2 2013 and has held it in 40 quarters since.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.